Group 1 - The core point of the article is that Sihuan Pharmaceutical (00460) has seen its stock price increase by over 4%, currently trading at HKD 1.87 with a transaction volume of HKD 66.5181 million [1] - Xuan Zhu Biotechnology is set to launch an initial public offering (IPO) from October 6 to October 10, planning to globally offer 67.335 million shares, with trading expected to commence on October 15 [1] - Xuan Zhu Biotechnology is a spin-off from Sihuan Pharmaceutical, indicating a strategic move to enhance its market presence [1] Group 2 - Sihuan Pharmaceutical's subsidiary, Meiyan Space, has developed a new product, "Frozen Beauty," which is an injectable sodium hyaluronate composite solution that has recently received a Class III medical device registration certificate from the National Medical Products Administration [1] - This product marks the first domestic launch of a water-light needle containing L-carnosine composite solution, highlighting innovation in the medical aesthetics market [1]
四环医药再涨超4% 轩竹生物今起招股 公司旗下“冻妍”获批上市